BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol 2020;17:687-705. [PMID: 32555420 DOI: 10.1038/s41571-020-0388-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Pace LE, Keating NL. Should Women at Lower-Than-Average Risk of Breast Cancer Undergo Less Frequent Screening? J Natl Cancer Inst 2021;113:953-4. [PMID: 33515224 DOI: 10.1093/jnci/djaa219] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang N, Gu Y, Chi J, Liu X, Xiong Y, Zhong C, Wang F, Wang X, Li L. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics. Front Genet 2021;12:721873. [PMID: 34408776 DOI: 10.3389/fgene.2021.721873] [Reference Citation Analysis]
3 Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJzerman MJ, Trainer AH. Heterogeneity in how women value risk-stratified breast screening. Genet Med 2021:S1098-3600(21)04129-0. [PMID: 34906505 DOI: 10.1016/j.gim.2021.09.002] [Reference Citation Analysis]
4 Houssami N, Kerlikowske K. AI as a new paradigm for risk-based screening for breast cancer. Nat Med 2022. [PMID: 35027759 DOI: 10.1038/s41591-021-01649-3] [Reference Citation Analysis]
5 Wolfson M, Gribble S, Pashayan N, Easton DF, Antoniou AC, Lee A, van Katwyk S, Simard J. Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. Genet Med 2021. [PMID: 34230637 DOI: 10.1038/s41436-021-01258-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Houssami N. Can population breast screening programs be leveraged to reduce the burden of breast cancer? Breast 2021;60:245-6. [PMID: 34801799 DOI: 10.1016/j.breast.2021.11.011] [Reference Citation Analysis]
7 Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res Treat 2021;189:593-8. [PMID: 34529196 DOI: 10.1007/s10549-021-06346-w] [Reference Citation Analysis]
8 Oparina N, Erlandsson MC, Fäldt Beding A, Parris T, Helou K, Karlsson P, Einbeigi Z, Bokarewa MI. Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts. Cancers (Basel) 2021;13:2209. [PMID: 34064473 DOI: 10.3390/cancers13092209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP. Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers (Basel) 2021;13:4150. [PMID: 34439302 DOI: 10.3390/cancers13164150] [Reference Citation Analysis]
10 Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The Perspective I I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y. Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. J Pers Med 2021;11:726. [PMID: 34442372 DOI: 10.3390/jpm11080726] [Reference Citation Analysis]
11 Knoppers BM, Bernier A, Granados Moreno P, Pashayan N. Of Screening, Stratification, and Scores. J Pers Med 2021;11:736. [PMID: 34442379 DOI: 10.3390/jpm11080736] [Reference Citation Analysis]
12 Lange M, Begolli R, Giakountis A. Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine. Noncoding RNA 2021;7:47. [PMID: 34449663 DOI: 10.3390/ncrna7030047] [Reference Citation Analysis]
13 Lah NAC, Gray R, Trigueros S. Synthesis, characterisation and cytotoxicity of gold microwires for ultra-sensitive biosensor development. Microb Cell Fact 2021;20:46. [PMID: 33596912 DOI: 10.1186/s12934-020-01478-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J. Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). J Pers Med 2021;11:511. [PMID: 34199804 DOI: 10.3390/jpm11060511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Veron L, Wehrer D, Caron O, Balleyguier C, Delaloge S. Autres approches en dépistage du cancer du sein. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.02.006] [Reference Citation Analysis]
16 Ramos-Medina R, López-Tarruella S, Del Monte-Millán M, Massarrah T, Martín M. Technical Challenges for CTC Implementation in Breast Cancer. Cancers (Basel) 2021;13:4619. [PMID: 34572846 DOI: 10.3390/cancers13184619] [Reference Citation Analysis]
17 Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med 2021;10:4677-96. [PMID: 34165267 DOI: 10.1002/cam4.4052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang H, Xu J, Gao B, Wang H, Huang J, Zhou J, Yang R, Yan F, Peng Y. Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy. Front Pharmacol 2021;12:750847. [PMID: 34867360 DOI: 10.3389/fphar.2021.750847] [Reference Citation Analysis]
19 Chiarelli AM, Walker MJ, Espino-Hernandez G, Gray N, Salleh A, Adhihetty C, Gao J, Fienberg S, Rey MA, Rabeneck L. Adherence to guidance for prioritizing higher risk groups for breast cancer screening during the COVID-19 pandemic in the Ontario Breast Screening Program: a descriptive study. CMAJ Open 2021;9:E1205-12. [PMID: 34933878 DOI: 10.9778/cmajo.20200285] [Reference Citation Analysis]
20 Blouin-Bougie J, Amara N, Simard J. Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers. J Pers Med 2021;11:540. [PMID: 34200634 DOI: 10.3390/jpm11060540] [Reference Citation Analysis]
21 Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet 2021;64:104350. [PMID: 34606975 DOI: 10.1016/j.ejmg.2021.104350] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang L, Liu J, Tai J, Zhou N, Huang T, Xue Y, Quan Z. A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer. Sci Rep 2021;11:15328. [PMID: 34321580 DOI: 10.1038/s41598-021-94784-3] [Reference Citation Analysis]
23 Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, Vale DB, Elder K, Procopio P, van Ravesteyn NT, Mutabi M, Canfell K, Nickson C; Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium. The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med 2021;151:106585. [PMID: 34217412 DOI: 10.1016/j.ypmed.2021.106585] [Reference Citation Analysis]
24 Kelley-Jones C, Scott S, Waller J. UK Women's Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study. Cancers (Basel) 2021;13:5813. [PMID: 34830965 DOI: 10.3390/cancers13225813] [Reference Citation Analysis]
25 Peng Y, Cong Y, Lei Y, Sun F, Xu M, Zhang J, Fang L, Hong H, Cai T. Transforming Passive into Active: Multimodal Pheophytin-Based Carbon Dots Customize Protein Corona to Target Metastatic Breast Cancer. Adv Healthc Mater 2022;:e2102270. [PMID: 35032116 DOI: 10.1002/adhm.202102270] [Reference Citation Analysis]
26 Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, Hippisley-Cox J. The current status of risk-stratified breast screening. Br J Cancer 2021. [PMID: 34703006 DOI: 10.1038/s41416-021-01550-3] [Reference Citation Analysis]
27 Zhao RP, Li Z, Li C, Xu K, Zhen LL, Song W, Shi JH. A Genetic Variant of the BTLA Gene is Related to Increased Risk and Clinical Manifestations of Breast Cancer in Chinese Women. Clin Breast Cancer 2020:S1526-8209(20)30337-2. [PMID: 33642196 DOI: 10.1016/j.clbc.2020.12.009] [Reference Citation Analysis]
28 Bae MS, Kim HG. Breast Cancer Risk Prediction Using Deep Learning. Radiology 2021;301:559-60. [PMID: 34491135 DOI: 10.1148/radiol.2021211446] [Reference Citation Analysis]
29 Louro J, Román M, Posso M, Vázquez I, Saladié F, Rodriguez-Arana A, Quintana MJ, Domingo L, Baré M, Marcos-Gragera R, Vernet-Tomas M, Sala M, Castells X; BELE and IRIS Study Groups. Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS One 2021;16:e0248930. [PMID: 33755692 DOI: 10.1371/journal.pone.0248930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Saghatchian M, Abehsera M, Yamgnane A, Geyl C, Gauthier E, Hélin V, Bazire M, Villoing-Gaudé L, Reyes C, Gentien D, Golmard L, Stoppa-Lyonnet D. Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. Breast Cancer Res Treat 2022. [PMID: 34994879 DOI: 10.1007/s10549-021-06445-8] [Reference Citation Analysis]
31 Pons-Rodriguez A, Marzo-Castillejo M, Cruz-Esteve I, Galindo-Ortego G, Hernández-Leal MJ, Rué M. [Moving toward personalized breast cancer screening: The role of Primary Care]. Aten Primaria 2022;54:102288. [PMID: 35477080 DOI: 10.1016/j.aprim.2022.102288] [Reference Citation Analysis]
32 Manouchehri E, Taghipour A, Ebadi A, Homaei Shandiz F, Latifnejad Roudsari R. Understanding breast cancer risk factors: is there any mismatch between laywomen perceptions and expert opinions. BMC Cancer 2022;22:309. [PMID: 35321682 DOI: 10.1186/s12885-022-09372-z] [Reference Citation Analysis]
33 Jiang Y, Wang D. Differential Expression of Blood Group Precursor Antigen in Human Breast Cancer Tissue. Int J Cancer Sci Ther 2020;2. [PMID: 32879924 DOI: 10.31487/j.ijcst.2020.01.04] [Reference Citation Analysis]
34 Zhang J, Shan B, Lin L, Dong J, Sun Q, Zhou Q, Chen J, Han X. Dissecting the Role of N6-Methylandenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer. Front Cell Dev Biol 2021;9:711859. [PMID: 34692676 DOI: 10.3389/fcell.2021.711859] [Reference Citation Analysis]
35 Chen X, Deng Y, Cao G, Liu X, Gu T, Feng R, Huo D, Xu F, Hou C. An ultrasensitive and point-of-care sensor for the telomerase activity detection. Anal Chim Acta 2021;1146:61-9. [PMID: 33461720 DOI: 10.1016/j.aca.2020.11.037] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Hosseinkazemi H, Samani S, O’neill A, Soezi M, Moghoofei M, Azhdari MH, Aavani F, Nazbar A, Keshel SH, Doroudian M, Shi D. Applications of Iron Oxide Nanoparticles against Breast Cancer. Journal of Nanomaterials 2022;2022:1-12. [DOI: 10.1155/2022/6493458] [Reference Citation Analysis]
37 Gastounioti A, Desai S, Ahluwalia VS, Conant EF, Kontos D. Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review. Breast Cancer Res 2022;24:14. [PMID: 35184757 DOI: 10.1186/s13058-022-01509-z] [Reference Citation Analysis]
38 Jahan S, Karim ME, Chowdhury EH. Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics. Biomedicines 2021;9:114. [PMID: 33530291 DOI: 10.3390/biomedicines9020114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Pashayan N, Antoniou AC, Lee A, Wolfson M, Chiquette J, Eloy L, Eisen A, Stockley TL, Nabi H, Brooks JD, Dorval M, Easton DF, Knoppers BM, Chiarelli AM, Simard J. Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening? J Pers Med 2021;11:916. [PMID: 34575693 DOI: 10.3390/jpm11090916] [Reference Citation Analysis]
40 Koopaie M, Kolahdooz S, Fatahzadeh M, Manifar S. Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta-analysis. Cancer Med 2022. [PMID: 35315584 DOI: 10.1002/cam4.4640] [Reference Citation Analysis]
41 Mbuya Bienge C, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Lévesque E, Hagan J, Walker MJ, Lapointe J, Dalpé G, Granados Moreno PG, Blackmore K, Wolfson M, Joly Y, Broeders M, Knoppers BM, Chiarelli AM, Simard J, Nabi H. Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. J Pers Med 2021;11:95. [PMID: 33540785 DOI: 10.3390/jpm11020095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Xu Y, Wu H, Xu G, Yin Z, Wang X, Chekhonin VP, Peltzer K, Li S, Li H, Zhang J, Ma W, Zhang C, Goyal S. Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China. The Breast Journal 2022;2022:1-14. [DOI: 10.1155/2022/7140884] [Reference Citation Analysis]
43 Jansen EEL, Ivanuš U, Jerman T, de Koning HJ, de Kok IMCM. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia. Gynecol Oncol 2021;160:118-27. [PMID: 33199028 DOI: 10.1016/j.ygyno.2020.10.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Dunlop K, Rankin NM, Smit AK, Salgado Z, Newson AJ, Keogh L, Cust AE. Acceptability of risk-stratified population screening across cancer types: Qualitative interviews with the Australian public. Health Expect 2021;24:1326-36. [PMID: 33974726 DOI: 10.1111/hex.13267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Roux A, Cholerton R, Sicsic J, Moumjid N, French DP, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Castells X, Ritchie D, Keatley D, Baron C, Delaloge S, de Montgolfier S. Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial. BMC Cancer 2022;22:507. [PMID: 35524202 DOI: 10.1186/s12885-022-09484-6] [Reference Citation Analysis]